https://pharminent.com/arrowheads-plozasiran-cuts-triglycerides-roughly-80-in-two-phase-3-trials/ 2026-07-22T20:17:25Z Pharminent en Arrowhead's Plozasiran Cuts Triglycerides Roughly 80% in Two Phase 3 Trials 2026-07-22T20:17:25Z Blog https://pharminent.com/trump-threatens-100-200-tariffs-on-imported-generic-drugs/ 2026-07-22T20:17:23Z Pharminent en Trump Threatens 100%–200% Tariffs on Imported Generic Drugs 2026-07-22T20:17:23Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-july-22-2026/ 2026-07-22T20:01:52Z Pharminent en Manufacturing Intelligence • Weekly Digest • July 22, 2026 2026-07-22T20:01:50Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-22-2026/ 2026-07-22T19:00:08Z Pharminent en Strategic News Watch • July 22, 2026 2026-07-22T15:59:06Z Blog https://pharminent.com/repligen-builds-in-cell-therapy-with-1-5bn-biolife-takeover/ 2026-07-22T19:05:06Z Pharminent en Repligen builds in cell therapy with $1.5bn BioLife takeover 2026-07-22T13:28:08Z Blog https://pharminent.com/us-generic-tariff-reprieve-on-the-rocks-as-trump-proposes-100-rate-in-2028/ 2026-07-22T19:08:14Z Pharminent en US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028 2026-07-22T10:41:55Z Blog https://pharminent.com/novo-nordisk-sues-eli-lilly-over-deceptive-glp-1-advertising/ 2026-07-21T20:53:07Z Pharminent en Novo Nordisk Sues Eli Lilly Over 'Deceptive' GLP-1 Advertising 2026-07-21T20:51:21Z Blog https://pharminent.com/novartis-ends-adc-holdout-with-up-to-1-5b-myricx-bio-deal/ 2026-07-21T20:51:18Z Pharminent en Novartis Ends ADC Holdout With Up-to-$1.5B Myricx Bio Deal 2026-07-21T20:51:18Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-july-21-2026/ 2026-07-21T20:43:41Z Pharminent en Oncology Intelligence Digest • July 21, 2026 2026-07-21T20:34:00Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-21-2026/ 2026-07-21T15:49:22Z Pharminent en Strategic News Watch • July 21, 2026 2026-07-21T15:49:20Z Blog https://pharminent.com/astrazeneca-positions-rare-diseases-at-center-of-80-billion-ambition/ 2026-07-20T20:55:29Z Pharminent en AstraZeneca Positions Rare Diseases at Center of $80 Billion Ambition 2026-07-20T20:55:29Z Blog https://pharminent.com/samsung-biologics-acquires-swiss-cdmo-polypeptide-in-1-81bn-all-cash-deal/ 2026-07-20T20:33:05Z Pharminent en Samsung Biologics Acquires Swiss CDMO PolyPeptide in $1.81bn All-Cash Deal 2026-07-20T20:33:01Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-july-20-2026/ 2026-07-20T20:25:03Z Pharminent en Rare Disease & Gene Therapy Digest • July 20, 2026 2026-07-20T20:25:01Z Blog https://pharminent.com/week-in-review/week-in-review-intelligence-brief-july-18-2026/ 2026-07-20T17:53:28Z Pharminent en Week in Review • INTELLIGENCE BRIEF • July 18, 2026 2026-07-20T17:53:26Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-20-2026/ 2026-07-20T15:55:53Z Pharminent en Strategic News Watch • July 20, 2026 2026-07-20T15:55:51Z Blog https://pharminent.com/lillys-ataibeckley-buy-validates-space-as-big-pharma-takes-note-of-psychedelics/ 2026-07-21T19:44:26Z Pharminent en Lilly's AtaiBeckley buy validates space as Big Pharma takes note of psychedelics 2026-07-20T15:11:47Z Blog https://pharminent.com/lundbeck-preps-for-key-bexicaserin-data-around-year-end/ 2026-07-20T20:52:14Z Pharminent en Lundbeck preps for key bexicaserin data around year-end 2026-07-20T12:59:54Z Blog